Substituted cycloalkanes for managing nephrogenic diabetes insipidus
AssigneeNephroDI Therapeutics, Inc.
InventorsJeff Sands, Janet Klein, Ish Khanna, Sivaram Pillarisetti
Life of this patent
Estimating the term…
Abstract
In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of compounds of the class of alkyl carboxylic acids, such as 1,1′-(decane-1,10-diyl)bis(cyclopropane-1-carboxylic acid), pharmaceutical salts or derivatives thereof, and the class of alkyl amides, such as 1,1′-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxamide), pharmaceutical salts or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
Claims72
A method for treating nephrogenic diabetes insipidus in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and 1,1′-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxylic acid) of the following structure:
- or a pharmaceutically acceptable salt thereof.
A method for treating nephrogenic diabetes insipidus in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and 1,1′-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxamide) of the following structure:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.